Kleanthis Xanthopoulos, Shoreline CEO
Fresh off Kite and BeiGene deals, Shoreline ups the ante with a hefty crossover. But the biotech insists it's in no rush
Though it may seem like Shoreline Biosciences is rapidly gaining momentum with a flurry of deals — and, now, a new funding round — Kleanthis Xanthopoulos …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
